About Shield Therapeutics (LON:STX)
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-156.666666666667
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX (0.15)
Return on Equity-38.71%
Return on Assets-36.22%
Shield Therapeutics (LON:STX) Frequently Asked Questions
What is Shield Therapeutics' stock symbol?
Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."
Where is Shield Therapeutics' stock going? Where will Shield Therapeutics' stock price be in 2018?
1 Wall Street analysts have issued 1-year price targets for Shield Therapeutics' stock. Their forecasts range from GBX 220 to GBX 265. On average, they expect Shield Therapeutics' share price to reach GBX 243.33 in the next year. View Analyst Ratings for Shield Therapeutics.
Who are some of Shield Therapeutics' key competitors?
Some companies that are related to Shield Therapeutics include Proteome Sciences (PRM), Bioblast Pharma (ORPN), Zosano Pharma (ZSAN), Dare Bioscience (DARE), ValiRx (VAL), Ariad Pharmaceuticals (ARIA), Cynapsus Therapeutics (CYNA), Dyax (DYAX), Kythera Biopharmaceuticals (KYTH), Ocata Therapeutics (OCAT), Receptos (RCPT), Relypsa (RLYP), Tobira Development (TBRA) and ZS Pharma (ZSPH).
Who are Shield Therapeutics' key executives?
Shield Therapeutics' management team includes the folowing people:
- Carl Andrew Sterritt, Chief Executive Officer, Director
- Karl David Keegan Ph.D., Interim Chief Financial Officer (Age 50)
- Jacqueline Mitchell, Vice President - Regulatory Affairs
- Paul Steckler, Vice President - Commercial Operations
- Angela Hildreth, Group Financial Controller and Head of Human Resources
- David Childs, Manufacturing Director
- Ashok Dhanrajgir, Non-Executive Director
- Lynn Drummond, Non-Executive Director (Age 55)
How do I buy Shield Therapeutics stock?
Shares of Shield Therapeutics and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Shield Therapeutics' stock price today?
One share of Shield Therapeutics stock can currently be purchased for approximately GBX 23.50.
How big of a company is Shield Therapeutics?
Shield Therapeutics has a market capitalization of £5.95 million.
How can I contact Shield Therapeutics?
Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.
MarketBeat Community Rating for Shield Therapeutics (STX)MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Shield Therapeutics (LON:STX)
No earnings announcements for this company have been tracked by MarketBeat.com
Shield Therapeutics (LON:STX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Shield Therapeutics (LON:STX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Shield Therapeutics (LON STX)
No insider trades for this company have been tracked by MarketBeat.com
Shield Therapeutics (LON STX) News Headlines
Shield Therapeutics (LON:STX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Shield Therapeutics (LON STX) Stock Chart for Friday, February, 23, 2018